We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.
FOSTER CITY, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
FOSTER CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
FOSTER CITY, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Interim data from initial dose escalation cohorts from Phase 1 CARDINAL trial of TERN-701 (allosteric BCR-ABL) in CML expected in 2H24 Top-line data from Phase 1 trial of TERN-601 (oral GLP-1...
FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
FOSTER CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.44 | -5.91397849462 | 7.44 | 8.415 | 6.92 | 1716892 | 7.90818897 | CS |
4 | 1.07 | 18.0438448567 | 5.93 | 8.415 | 5.64 | 1304749 | 7.0436943 | CS |
12 | 0.8 | 12.9032258065 | 6.2 | 8.415 | 4.32 | 993359 | 6.21411706 | CS |
26 | 0.57 | 8.86469673406 | 6.43 | 8.68 | 4.32 | 881843 | 6.51252341 | CS |
52 | -3.71 | -34.6405228758 | 10.71 | 13.03 | 3.26 | 781472 | 6.66120179 | CS |
156 | -8.61 | -55.1569506726 | 15.61 | 15.955 | 1.45 | 410043 | 7.06157643 | CS |
260 | -9.95 | -58.7020648968 | 16.95 | 28.36 | 1.45 | 381063 | 7.670717 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions